Clarkston Capital Partners LLC Grows Stake in IQVIA Holdings Inc. (NYSE:IQV)

Clarkston Capital Partners LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 60.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,000 shares of the medical research company's stock after acquiring an additional 9,000 shares during the quarter. Clarkston Capital Partners LLC's holdings in IQVIA were worth $4,716,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of IQVIA in the 4th quarter worth about $336,041,000. Raymond James Financial Inc. purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $236,120,000. American Century Companies Inc. boosted its position in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after purchasing an additional 905,960 shares in the last quarter. JPMorgan Chase & Co. increased its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB raised its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on IQV shares. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target for the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Robert W. Baird cut their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Mizuho decreased their price objective on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a report on Wednesday. Finally, Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Stock Performance

NYSE IQV traded up $0.86 on Friday, hitting $144.08. 1,050,606 shares of the company traded hands, compared to its average volume of 1,373,754. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The business's 50 day moving average price is $183.41 and its 200-day moving average price is $200.24. The company has a market capitalization of $25.40 billion, a price-to-earnings ratio of 19.21, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.